Fly News Breaks for September 13, 2017
Sep 13, 2017 | 07:28 EDT
Canaccord analyst John Newman raised his price target on Aldeyra to $27 from $12 following the release of positive clinical and statistically significant data in its Phase 2a dry eye study. The analyst believes the data could provide strong support for future approval. Newman maintained his Buy rating on Aldeyra shares.
News For ALDX From the Last 2 Days
There are no results for your query ALDX